This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7%
by Zacks Equity Research
Galectin Therapeutics, Inc. (GALT) shares rose nearly 17% in the last trading session.
Amgen Files for Xgeva Label Expansion, To Include Myeloma
by Zacks Equity Research
Amgen, Inc. (AMGN) recently announced that it has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the label of its key drug, Xgeva.
Sanofi's (SNY) Diabetes Drug Toujeo Lowers Hypoglycemia Risk
by Zacks Equity Research
A real-world observational study showed that when type 2 diabetes patients on basal insulin switched to Toujeo, it led to a significant reduction in risk of hypoglycemia without compromising blood sugar control
AbbVie's (ABBV) Humira Drug Label Update Approved by FDA
by Zacks Equity Research
AbbVie Inc.'s (ABBV) announced that the FDA has approved the inclusion of moderate to severe fingernail psoriasis data on the label of AbbVie???s multi-utility TNF blocker drug, Humira
New Strong Buy Stocks for March 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Catalyst Pharmaceuticals (CPRX) Jumps: Stock Gains 18.2%
by Zacks Equity Research
Catalyst Pharmaceuticals, Inc. (CPRX) moved big last session, as its shares rose over 18% on the day.
5 Cheap PEG Picks for Value Investors Right Now
by Zacks Equity Research
PEG is the ratio with the earnings growth component in it.
Allergan's Dermal Filler for Wrinkle Correction Gets FDA Nod
by Zacks Equity Research
Allergan plc (AGN) announced yesterday that the FDA has approved its Juvederm Vollure XC dermal filler for correction of facial wrinkles and folds in adults over the age of 21.
AstraZeneca (AZN) Gets Another CRL for ZS-9; Inks COPD Deal
by Zacks Equity Research
London based AstraZeneca plc (AZN) received a second Complete Response Letter (CRL) from the FDA for its new drug application (NDA) for investigational drug ZS-9.
Is Grifols a Great Stock for Value Investors?
by Zacks Equity Research
Let's focus on Grifols, S.A. (GRFS) stock and find out if it is a good choice for value-oriented investors right now or not.
Aurinia (AUPH) Catches Eye: Stock Moves up 8.5% in Session
by Zacks Equity Research
Aurinia Pharmaceuticals Inc. (AUPH) moved big last session, as its shares rose above 8% on the day.
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 8.6%
by Zacks Equity Research
Esperion Therapeutics, Inc. (ESPR) moved big last session, as its shares rose above 8% on the day.
New Strong Buy Stocks for March 9th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Infinity Pharmaceuticals (INFI) Catches Eye: Stock Up 13.5%
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) saw its shares rise almost 7% in the last trading session.
Hologic (HOLX) to Divest Blood Screening Business to Grifols
by Zacks Equity Research
Hologic, Inc. (HOLX) recently inked a deal to divest its stake in the blood screening business.
The Power of New Analyst Coverage
by Kevin Matras
Kevin Matras shows why stocks with new analyst coverage are stocks you want to have. Highlighted stocks include GRFS, PRGN, GWRE, ABM and THG.